Charles River Laboratories International has acquired SAMDI Tech for $50 million.
 
The two companies have been partners since 2018.
 
“The acquisition of SAMDI Tech’s cutting-edge, high-throughput screening technology further strengthens Charles River’s drug discovery capabilities and enhances our unique ability to serve as an integrated partner to support our clients’ early-stage research,” said James Foster, chairman, president and CEO Charles River Laboratories. “SAMDI Tech’s platform combined with our premier, end-to-end drug discovery portfolio will generate better data and faster hit identification and is another step to accelerate our clients’ drug discovery efforts.”
 
Charles River said that its end-to-end portfolio and scientific expertise, combined with SAMDI’s MS technology and expertise in assay solutions, has the potential to accelerate and augment clients’ discovery efforts by measuring biochemical activities and identifying binding interactions for virtually any small molecule drug target.
 
In addition, Charles River said that the acquisition will also provide its clients with seamless access to the label-free HTS MS platform and create a comprehensive library of drug discovery solutions.